© 2018

Behavioral Neurobiology of Psychedelic Drugs

  • Adam L. Halberstadt
  • Franz X. Vollenweider
  • David E. Nichols

Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 36)

Table of contents

  1. Front Matter
    Pages i-x
  2. Katrin H. Preller, Franz X. Vollenweider
    Pages 1-1
  3. Juan F. López-Giménez, Javier González-Maeso
    Pages 45-73
  4. L. Lladó-Pelfort, P. Celada, M. S. Riga, E. Troyano-Rodríguez, N. Santana, F. Artigas
    Pages 75-105
  5. David A. Martin, Charles D. Nichols
    Pages 137-158
  6. Adam L. Halberstadt, Mark A. Geyer
    Pages 159-199
  7. Lisa E. Baker
    Pages 201-219
  8. Katrin H. Preller, Franz X. Vollenweider
    Pages 221-256
  9. Michael Kometer, Franz X. Vollenweider
    Pages 257-282
  10. Michael P. Bogenschutz, Stephen Ross
    Pages 361-391
  11. Frederick S. Barrett, Roland R. Griffiths
    Pages 393-430

About this book


This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action.  Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.


MDMA entactogens hallucinogens psychedelics psychotomimetics

Editors and affiliations

  • Adam L. Halberstadt
    • 1
  • Franz X. Vollenweider
    • 2
  • David E. Nichols
    • 3
  1. 1.Department of PsychiatryUniversity of California San DiegoLa JollaUSA
  2. 2.Psychiatric University Hospital, Heffter Research Center ZurichUniversity of ZurichZurichSwitzerland
  3. 3.Division of Chemical Biology and Medicinal ChemistryUniversity of North CarolinaChapel HillUSA

Bibliographic information

  • Book Title Behavioral Neurobiology of Psychedelic Drugs
  • Editors Adam L. Halberstadt
    Franz X. Vollenweider
    David E. Nichols
  • Series Title Current Topics in Behavioral Neurosciences
  • Series Abbreviated Title CTBN
  • DOI
  • Copyright Information Springer-Verlag GmbH Germany, part of Springer Nature 2018
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-662-55878-2
  • Softcover ISBN 978-3-662-58563-4
  • eBook ISBN 978-3-662-55880-5
  • Series ISSN 1866-3370
  • Series E-ISSN 1866-3389
  • Edition Number 1
  • Number of Pages X, 430
  • Number of Illustrations 38 b/w illustrations, 158 illustrations in colour
  • Topics Neurosciences
    Medicinal Chemistry
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals


“This book brings together the latest basic and clinical research into the underlying mechanism of action, effects, and possible clinical uses of psychedelic drugs. … It brings together current knowledge regarding this class of drugs pharmacology, neurobiological effects, subjective experience, and therapeutic effects. … It brings together preclinical and clinical data, which will be of interest to anyone involved with or curious about this category of drugs.” (Michael Easton, Doody's Book Reviews, September, 2018)